Literature DB >> 18064660

Osteoporosis in children with cancer.

Inge M van der Sluis1, Marry M van den Heuvel-Eibrink.   

Abstract

As increasing numbers of childhood cancer patients are surviving, the long-term complications of the disease and its treatment have become ever more increasingly important. Reduced bone mineral density and increased fracture risk have been reported during and after treatment of children with cancer. The causes of osteoporosis are multifactorial. Among others, the disease itself, chemotherapy, irradiation and genetic susceptibility play a role. Bone mineral density in later life depends largely on the peak bone mass achieved in adolescence or young adulthood. Therefore, optimizing peak bone mass is of clinical importance. Preventive and therapeutic strategies, such as calcium and vitamin D supplementation, physical activity and bisphosphonates, are considered. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18064660     DOI: 10.1002/pbc.21407

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  12 in total

1.  Short and long-term impairments of cardiopulmonary fitness level in previous childhood cancer cases: a systematic review.

Authors:  Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda
Journal:  Support Care Cancer       Date:  2018-09-25       Impact factor: 3.603

2.  Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma.

Authors:  Ulrike Michaela Pirker-Frühauf; Jörg Friesenbichler; Ernst-Christian Urban; Barbara Obermayer-Pietsch; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2012-07-18       Impact factor: 4.176

3.  Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma.

Authors:  Ju Hyun Ahn; Wan Hyeong Cho; Jun Ah Lee; Dong Ho Kim; Ju-Hee Seo; Jung Sub Lim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2015-09-30

4.  Alterations of bone mineral metabolism of children with different cell lineage types of acute lymphoblastic leukaemia under chemotherapy.

Authors:  A Tragiannidis; Ch Dokos; V Sidi; Th Papageorgiou; D Koliouskas; M Karamouzis; Ch Papastergiou; I Tsitouridis; G Katzos; I Rousso; F Athanassiadou-Piperopoulou
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

5.  Physical Activity, Fitness, and Cardiometabolic Risk Factors in Adult Survivors of Childhood Cancer with a History of Hematopoietic Cell Transplantation.

Authors:  Megan E Slater; Julia Steinberger; Julie A Ross; Aaron S Kelly; Eric J Chow; Ildiko H Koves; Paul Hoffmeister; Alan R Sinaiko; Anna Petryk; Antoinette Moran; Jill Lee; Lisa S Chow; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-10       Impact factor: 5.742

6.  Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Authors:  Jae Min Lee; Ji Eun Kim; Soon Hwan Bae; Jeong Ok Hah
Journal:  Blood Res       Date:  2013-06-25

Review 7.  Diet and physical activity in childhood cancer survivors: a review of the literature.

Authors:  Melinda R Stolley; Jacqueline Restrepo; Lisa K Sharp
Journal:  Ann Behav Med       Date:  2010-06

8.  Pediatric Hodgkin lymphoma survivors at negligible risk for significant bone mineral density deficits.

Authors:  Sue C Kaste; Monika L Metzger; Anum Minhas; Zang Xiong; Shesh N Rai; Kirsten K Ness; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

9.  Physical activity barriers, preferences, and beliefs in childhood cancer patients.

Authors:  Wilhelmenia L Ross; Alyssa Le; Daniel J Zheng; Hannah-Rose Mitchell; Jaime Rotatori; Fangyong Li; John T Fahey; Kirsten K Ness; Nina S Kadan-Lottick
Journal:  Support Care Cancer       Date:  2018-01-27       Impact factor: 3.603

10.  Bone Loss in Pediatric Survivors of Acute Lymphoblastic Leukemia.

Authors:  Arzu Duygu Donmez; Pamir Isik; Semra Cetinkaya; Nese Yarali
Journal:  Eurasian J Med       Date:  2018-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.